Harrison-Gómez C, Harrison-Ragle A, Macías-Hernández A, Guerrero-Sánchez V

Language: Spanish
References: 23
Page: 219-225
PDF size: 123.29 Kb.

ABSTRACT

Background: mitochondrial DNA (DNAmt) mutations are associated with several clinical manifestations affecting different systems. They are usually under diagnosed even the relatively high prevalence in certain populations. The diagnosis can be established on clinical data, histopathologic studies and biochemical abnormalities in the respiratory chain, or the finding of the specific causal mutation in the DNAmt.
Clinical case: we describe a patient and her family history, affecting neurologic, cardiovascular and endocrine systems. We established the diagnosis of MELAS syndrome (mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes) with the collaboration of the Laboratory of Molecular Neurogenetics of the Department of Neurology of Columbia University in New York, NY, USA to whom we sent peripheral blood DNA. The DNA was amplified by polymerase chain reaction (PCR) and subjected to restriction fragment length polymorphism analysis. The study was positive for the point mutation adenine (A) for guanine (G) on the position 3243 of DNAmt. We make a brief clinical description. We also review DNAmt, related mutations and clinical expressions of the disease. We also highlighted the prevalence of DNAmt mutations in certain clinical situations.

REFERENCES

1. Luft R, Ikkos D, Palmieri G, Ernster L, Afzelius B. A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study. J Clin Invest 1962;41:1776-1804.

2. Schatz G. The isolation of possible mitochondrial precursor structures from aerobically grown baker´s yeast. Biochem Biophys Res Commun 1963;12: 448-451.

3. Holt IJ, Morgan-Hughes JA, Harding AE. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 1988;331(6158):717-719.

4. Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, Lezza AM, et al. Mitochondrial DNA mutation associated with Leber´s hereditary optic neuropathy. Science 1988;242(4884):1427-1430.

5. Goto Y, Nonaka I, Horai S. A mutation in the tRNALeu (UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyophaties. Nature 1990;348(6302):651-653.

6. Gene Reviews. Mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes [MELAS]. Disponible en http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi? book= gene&part=melas

7. The Report of the Committee on the Human Mitochondrial genome. Disponible en http://www.mitomap.org

8. DiMauro S, Schon EA. Mitochondrial respiratorychain disease. N Engl J Med 2003;348(26):2656-2668.

9. Scaglia F. MELAS syndrome. Disponible en http://www.emedicine.com/PED/topic1406.htm

10. Kadowaki T, Kadowaki H, Mori Y, Tobe K, Sakuta R, Suzuki Y, et al. A subtype of diabetes mellitus associated with a mutation of mithocondrial DNA. N Engl J Med 1994;330(14):962-968.

11. Willems P.J. Genetic causes of hearing loss. N Engl J Med 2000;342(15):1101-1109.

12. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies an American Heart Association Scientific Statement. Circulation 2006;113(14):1807-1816.

13. Dickerson BC, Holtzman D, Grant PE, Tian Di. Case 36-2005. A 61 year old woman with seizure, disturbed gait, and altered mental status. N Engl J Med 2005;53(21):2271-2280.

14. Calderón-Garcidueñas AL, Pérez-Loria O, Sagástegui JA, Farías-García R. Oftalmoplegía progresiva externa secundaria a miopatía mitocondrias. Presentación de un caso y revisión de la literatura. Gac Med Mex 2000;136(3):267-271.

15. Tapia-Pérez JH, Rodríguez-Leyva I, Oros-Ovalle C. Síndrome de sobreposición MELAS/MERRF: informe de un caso y revisión de la literatura. Rev Mex Neuroci 2003;4(5):360-365.

16. Barrera-Ramírez CF, Barragán-Campos HM, Sánchez-Guerrero J, García-Ramos G, Vega Boada F, Estanol B. The other genome: the clinical concept of mitochondrial cytopathies or disorders of oxidative phosphorylation. Rev Invest Clin 1999; 51(2):121-134.

17. Barrera-Ramírez CF, Barragán-Campos HM, Sánchez-Guerrero J. Mutations of the mitochondral genome and its clinical expresión in cardiology. Gac Med Mex 2000;136(6):585-594.

18. Solano A, Playán A, López-Pérez MJ, Montoya J. Genetic disease of the mitochondral DNA in humans. Salud Publica Mex 2001;43(2):151-161.

19. García-Ramos G, Téllez-Zenteno JF. Contributions of genetics to neurology. Rev Invest Clin 2003;55 (2):207-215.

20. Johns DR. Seminars in medicine of the Beth Istael Hosptial, Boston. Mitochondral DNA and disease. N Engl J Med 1995;333(10):638-644.

21. Barragán-Campos HM, Vallée JN, Lo D, Barrera-Ramírez CF, Argote-Greene M, Sánchez-Guerrero J, et al. Brain magnetic resonance imaging findings in patients with mitochondral cytopathies. Arch Neurol 2005;62(5):737-742.

22. Shankse S, Pancrudo J, Kaufmann P, Engelstad K, Jhung S, Lu J, et al. Varying loads of the mitochondrial DNA A3243G mutation in different tissues: implications for diagnoses. Am J Med Genet A 2004; 130A(2):134-137.

23. Majamaa K, Moilanen JS, Uimonen S, Remes AM, Salmela PI, Kärpä M, et al. Epidemiology of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes: prevalence of the mutation in adult population. Am J Human Genet 1998;63(2):447-454.